pacritinib activity against myelofibrosis
Published 4 years ago • 772 plays • Length 5:10Download video MP4
Download video MP3
Similar videos
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
1:45
design and results of pacritinib for myelofibrosis trial (persist-1)
-
1:42
consistency of pacritinib in patients with mf: pooled analysis from persist-1 & persist-2
-
2:18
results of persist-1 & persist-2 studies of pacritinib vs best alternative therapy in myelofibrosis
-
9:04
how are et, pv and myelofibrosis monitored?
-
3:48
efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from momentum
-
5:10
what are the treatment options for myelofibrosis?
-
2:10
phase i study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
2:48
recent updates on pacritinib in myelofibrosis
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
0:46
the role of pacritinib in managing thrombocytopenia in patients with myelofibrosis
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
3:20
safety and anemia outcomes with momelotinib vs pacritinib in patients with myelofibrosis
-
3:38
manifest: pelabresib in combination with ruxolitinib in myelofibrosis
-
1:46
the efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia
-
1:15
potential approval of pacritinib for the treatment of myelofibrosis
-
1:32
panobinostat plus ruxolitinib in myelofibrosis
-
1:59
pacritinib versus ruxolitinib in patients with myelofibrosis and thrombocytopenia
-
0:54
study design for persist-2 and other upcoming trials of pacritinib
-
4:35
pacritinib moving forwards for myelofibrosis